U.S. waives tariffs on certain speciality drugs from 20 countries, including India
2-minute summary
The United States has announced a zero per cent ad valorem tariff rate on eligible specialized drug imports from 20 countries, including India. This exemption covers critical health sectors such as rare disease treatments, cell and gene therapies, infertility treatments, antibody-drug conjugates (ADCs), and animal pharmaceuticals, along with their associated ingredients and components. The exemption stems from the implementation of a proclamation issued by the U.S. President under Section 232 of the Trade Expansion Act, which otherwise imposes steep 100% tariffs on certain patented pharmaceutical imports to encourage domestic U.S. manufacturing. Qualifying countries received this waiver because they maintain a current or forthcoming trade and security framework agreement with the U.S. Generic pharmaceutical products and their ingredients remain unaffected by the Section 232 tariffs. India's specialized pharmaceutical exporters stand significantly shielded from potential trade barriers due to this targeted zero-tariff classification.
Why it's in the news
The U.S. Commerce Department published a list in the Federal Register granting a zero per cent tariff waiver on specialized drug imports from India and 19 other countries under Section 232 of the Trade Expansion Act, shielding key medical exports from impending high tariff duties.
Facts to remember
- The United States announced a zero per cent ad valorem tariff rate on eligible specialized drug imports from 20 countries, including India.
- The tariff exemption stems from a proclamation issued by the U.S. President under Section 232 of the Trade Expansion Act.
- The waiver covers critical health sectors like rare disease treatments, cell and gene therapies, infertility treatments, antibody-drug conjugates, and animal pharmaceuticals.
- Qualifying countries received this waiver because they maintain a current or forthcoming trade and security framework agreement with the U.S.
- Generic pharmaceutical products and their ingredients remain unaffected by the Section 232 tariffs.
Background and context
The United States has increasingly utilized trade instruments such as Section 232 of the Trade Expansion Act—historically applied to national security-related imports like steel and aluminum—to reshape pharmaceutical supply chains and incentivize domestic production of critical medical goods. President Donald Trump's proclamation targeting patented pharmaceuticals, biologics, and associated ingredients sought to curb foreign reliance in high-end healthcare sectors. However, recognizing integrated global supply chains and the strategic necessity of specialized treatments (such as rare disease drugs, cell therapies, and gene therapies), the U.S. administration carved out exemptions for nations that share strategic trade and security frameworks, shielding key developing and advanced pharmaceutical exporters like India.
International organisations
- World Customs Organisation (WCO) — Provides standardized definitions for international trade terms, such as ad valorem tariffs.
Mains practice: Examine the implications of unilateral tariff measures and trade protectionism by major economies on India's pharmaceutical export sector.
Introduction
India, known as the 'pharmacy of the world', plays a pivotal role in global healthcare by supplying affordable generic medicines and specialized formulations. However, rising protectionism and trade measures by major economies like the U.S. pose both structural challenges and strategic opportunities for Indian exporters.
Key Implications of U.S. Tariff Measures
• Protection of Specialized Segments: Recent exemptions granting zero per cent tariffs on specialized drugs (such as cell/gene therapies and rare disease treatments) shield high-value Indian exports, acknowledging the deeply integrated nature of global medical supply chains.
• Shift Toward Domestic Manufacturing: U.S. policies invoking measures like Section 232 aim to incentivize domestic pharmaceutical production, compelling Indian firms to adapt through localized investments or enhanced technological integration.
• Focus on Generics vs. Patented Drugs: While generic pharmaceuticals are frequently insulated from strict trade barriers due to affordability concerns, patented drugs and biologics face stricter scrutiny, pushing Indian R&D toward complex generics and biosimilars.
• Strategic Trade Frameworks: Tariff exemptions are increasingly linked to bilateral trade and security agreements, underscoring the convergence of geopolitical alignment and economic policy.
Conclusion
While protectionist headwinds create short-term policy uncertainties, India's robust manufacturing ecosystem, skilled scientific workforce, and strategic trade alignments ensure its enduring centrality in the global pharmaceutical landscape, provided Indian firms continually climb the value chain toward high-end therapeutics.
Prelims practice questions
Q1. Consider the following statements regarding the U.S. tariff measures on pharmaceutical imports: 1. The zero per cent tariff waiver granted to India and other countries covers generic pharmaceutical products and their associated ingredients. 2. The tariff adjustments and exemptions were implemented under Section 232 of the U.S. Trade Expansion Act. Which of the statements given above is/are correct?
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer: B. Statement 1 is incorrect because generic pharmaceutical products and their associated ingredients are not subject to the Section 232 pharmaceutical tariffs in the first place; the zero tariff waiver specifically applies to certain specialized drugs like rare disease treatments, cell and gene therapies, and animal pharmaceuticals from qualifying countries. Statement 2 is correct as the exemptions are part of the implementation of the proclamation adjusting imports under Section 232 of the Trade Expansion Act.
Q2. The term 'ad valorem tariff', sometimes seen in international trade news, is best defined as:
- A fixed monetary levy imposed per unit of imported physical quantity or weight.
- An emergency trade barrier applied exclusively during a declared national security crisis.
- A tariff charged as a set percentage of the monetary value of the goods being imported.
- A voluntary export restriction agreed upon mutually between two trading partner nations.
Answer: C. An ad valorem tariff is defined as a tax levied as a fixed percentage of the monetary value of the imported goods, as distinct from specific tariffs which are charged as a fixed sum per unit of quantity.
Q3. Consider the following statements regarding India's pharmaceutical sector in global trade: 1. India is widely recognized globally as a major supplier of affordable generic medicines and active pharmaceutical ingredients (APIs). 2. Specialized pharmaceutical exports from India include treatments for rare diseases, cell therapies, and gene therapies. Which of the statements given above is/are correct?
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer: C. Both statements are correct. India is a global leader in generic drugs and APIs ('pharmacy of the world'), and Indian pharmaceutical companies are increasingly expanding into specialized, high-end medical treatments, including rare disease drugs, cell therapies, and advanced biological products.
Revision flashcards
- What does 'ad valorem' tariff mean in international trade? A tariff levied as a set percentage of the monetary value of the goods to be taxed.
- Under which U.S. legislative act were the recent pharmaceutical tariff proclamations implemented? Section 232 of the U.S. Trade Expansion Act.
- Are generic pharmaceutical products subject to the U.S. Section 232 specialized pharmaceutical tariffs? No, generic pharmaceutical products and their associated ingredients are exempt from these specific Section 232 tariffs.
- What types of specialized products qualify for zero per cent tariff rates under the U.S. Commerce Department notice? Drugs designated for rare diseases, infertility treatments, cell therapies, gene therapies, antibody-drug conjugates (ADCs), and animal pharmaceuticals (along with their components).
- Why did qualifying countries receive a zero per cent tariff waiver under the U.S. pharmaceutical proclamation? Because they maintain a current or forthcoming trade and security framework agreement with the United States.